The impact of researchers
-
July 8
GLP-1 receptor agonists not tied to higher overall pancreatitis risk, study finds
-
July 10
A target trial emulation found GLP-1 receptor agonists carry an early drug-induced risk offset by later reductions in alcohol and hypertriglyceridemia-related pancreatitis.
Browse By
Biliary Tract
Colon
Esophagus
Liver
Pancreas
Small Bowel
Stomach
The GI hospitalist: A practice-changing health care opportunity
-
April 23
-
by Vasili Kalas, MD, PhD
The model is reshaping inpatient care, despite slow national adoption.
Pancreatic cystic lesions: A case-based approach
-
April 17
-
by Ross C.D. Buerlein, MD , Himesh B. Zaver, MD , Vanessa M. Shami, MD
Dr. Vanessa Shami, along with Drs. Ross Buerlein and Himesh Zaver, describe characteristic cyst findings on cross-sectional and endoscopic sonographic imaging, fluid analysis results, and management.
Navigating primary sclerosing cholangitis: Diagnosis and the 5 pillars of management
-
February 1
-
by Judy A. Trieu, MD, MPH, Mahesh Krishna, MD, David N. Assis, MD
Primary sclerosing cholangitis remains a challenging disease to diagnose and manage, due to varying presentations, associated disease processes, and lack of targeted treatment.
The Latest
GLP-1 receptor agonists not tied to higher overall pancreatitis risk, study finds
-
by Matthew Solan
A target trial emulation found GLP-1 receptor agonists carry an early drug-induced risk offset by later reductions in alcohol and hypertriglyceridemia-related pancreatitis.
AI colonoscopy tool boosts adenoma detection in VA network, study finds
-
by Doug Brunk
In a cluster-randomized study of more than 334,000 colonoscopies across the Veterans Health Administration, facilities equipped with computer-aided detection raised adenoma detection rates by about 4 percentage points without lengthening withdrawal times.
Gastric cancer risk may emerge earlier in several Hispanic and Asian populations
-
by Henry Thomas
Several Hispanic and Asian populations reached the noncardia gastric cancer incidence of non-Hispanic White adults aged 60 to 69 by ages 40 to 59, a SEER analysis found.
Updated POWER guidance puts GI specialists at the center of obesity treatment
-
by Doug Brunk
The update weaves anti-obesity medications, endoscopic therapies, and bariatric surgery into a stepped, individualized approach to weight management.
The impact of researchers
-
by AGA
The AGA Research Foundation helps fund investigators like Sara Di Rienzi, PhD, whose microbiome research may open new paths for understanding and treating GI disease.
